TET2 and neoplasm: CAR-T cells containing the 4-1BB intracellular domain improved tumor treatment outcomes in mice after TET2 knockout, whereas CD28 signaling CAR-T cells exhibited no notable differences in cell differentiation or antitumor efficacy before versus after TET2 knockout.